Impact of prior cancer on eligibility for lung cancer clinical trials

Journal of the National Cancer Institute

Volumn 106, Issue 11, 2014, Pages

  Gerber, David E ^a,b   Laccetti, Andrew L ^b   Xuan, Lei ^b   Halm, Ethan A ^a,b   Pruitt, Sandi L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; LUNG CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SECONDARY ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; INFORMATION PROCESSING; LUNG NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; NEOPLASM; PATIENT SELECTION; PROCEDURES; SMALL CELL LUNG CARCINOMA; STANDARDS; SURVIVOR; TIME FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; SEER PROGRAM; SMALL CELL LUNG CARCINOMA; SURVIVORS; TIME FACTORS; UNITED STATES;

EID: 84930407230     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju302     Document Type: Article

References (29)

1. Friedman MA, Cain DF. National Cancer Institute sponsored cooperative clinical trials. Cancer. 1990;65(10 Suppl):2376-2382.
2. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726.
3. Tournoux C, Katsahian S, Chevret S, et al. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer. 2006;106(2):258-270.
4. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626-4631.
5. Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007;109(3):465-476.
6. Hietanen PS, Aro AR, Holli KA, et al. A short communication course for physicians improves the quality of patient information in a clinical trial. Acta Oncol. 2007;46(1):42-48.
7. Avis NE, Smith KW, Link CL, et al. Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol. 2006;24(12):1860-1867.
8. Ross S, Grant A, Counsell C, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143-1156.
9. Rasco DW, Xie Y, Yan J, et al. The impact of consenter characteristics and experience on patient interest in clinical research. Oncologist. 2009;14(5):468-475.
10. Gerber DE, Rasco DW, Skinner CS, et al. Consent timing and experience: modifiable factors that may influence interest in clinical research. J Oncol Pract. 2012;8(2):91-96.
11. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728-1733.
12. Lemieux J, Goodwin PJ, Pritchard KI, et al. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol. 2008;26(27):4458-4465.
13. Gotay CC. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med. 1991;33(5):569-577.
14. McCusker J, Wax A, Bennett JM. Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry. Am J Clin Oncol. 1982;5(2):227-236.
15. Kotwall CA, Mahoney LJ, Myers RE, et al. Reasons for non-entry in randomized clinical trials for breast cancer: a single institutional study. J Surg Oncol. 1992;50(2):125-129.
16. Lee JY, Breaux SR. Accrual of radiotherapy patients to clinical trials. Cancer. 1983;52(6):1014-1016.
17. Simon MS, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004;22(11):2046-2052.
18. Fuks A, Weijer C, Freedman B, et al. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol. 1998;51(2):69-79.
19. Rosner B. Fundamentals of Biostatistics. 5th Edition. Duxbury Thomson Learning, Australia.
20. Filion M, Forget G, Brochu O, et al. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment. Clin Trials. 2012;9(5):652-659.
21. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233-1240.
22. Ahn DH, Mehta N, Yorio JT, et al. Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013;14(6):644-650.
23. Koppe MJ, Zoetmulder FA, Van Zandwijk N, et al. The prognostic significance of a previous malignancy in operable non-small cell lung cancer. Lung Cancer. 2001;32(1):47-53.
24. Utsumi T, Fujii Y, Takeda S, et al. Clinical study on lung cancer as a second primary cancer. Surg Today. 1998;28(5):487-491.
25. Massard G, Ducrocq X, Beaufigeau M, et al. Lung cancer following previous extrapulmonary malignancy. Eur J Cardiothorac Surg. 2000;18(5):524-528.
26. NCI Cancer Treatment Evaluation Program (CTEP): Guidelines Regarding the Inclusion of Cancer Survivors and HIV-positive Individuals on Clinical Trials. 2008. Available at: http://ctep. cancer.gov/protocolDevelopment/policies-hiv.htm. Accessed on January 6, 2014.
27. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
28. Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol. 2010;5(10):1529-1535.
29. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20-37.